Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study
Year: 2011
Type: article
Study design: Observational Study
Abstract: BACKGROUND: A recently published genome-wide association study (GWAS) of late-onset Alzheimer's disease (LOAD) revealed genome-wide significant association of variants in or near MS4A4A, CD2AP, EPHA1 and CD33. Meta-analyses of this and a previously published GWAS revealed significant association at ABCA7 and MS4A, independent evidence for association of CD2AP, CD33 and EPHA1 and an opposing yet significant association of a variant near ARID5B. In this study, we genotyped five variants (in or near CD2AP, EPHA1, ARID5B, and CD33) in a large (2,634 LOAD, 4,201 controls), independent dataset comprising six case-control series from the USA and Europe. We performed meta-analyses of the association of these variants with LOAD and tested for association using logistic regression adjusted by age-at-diagnosis, gender, and APOE ε4 dosage. RESULTS: We found no significant evidence of series heterogeneity. Associations with LOAD were successfully replicated for EPHA1 (rs11767557; OR = 0.87, p = 5 × 10-4) and CD33 (rs3865444; OR = 0.92, p = 0.049), with odds ratios comparable to those previously reported. Although the two ARID5B variants (rs2588969 and rs494288) showed significant association with LOAD in meta-analysis of our dataset (p = 0.046 and 0.008, respectively), the associations did not survive adjustment for covariates (p = 0.30 and 0.11, respectively). We had insufficient evidence in our data to support the association of the CD2AP variant (rs9349407, p = 0.56). CONCLUSIONS: Our data overwhelmingly support the association of EPHA1 and CD33 variants with LOAD risk: addition of our data to the results previously reported (total n > 42,000) increased the strength of evidence for these variants, providing impressive p-values of 2.1 × 10-15 (EPHA1) and 1.8 × 10-13 (CD33).
Source: Molecular Neurodegeneration
Authors: Minerva M Carrasquillo, Olivia Belbin, Talisha A Hunter, Li Ma, Gina D Bisceglio, Fanggeng Zou, Julia E Crook, V Shane Pankratz, Sigrid B Sando, Jan O Aasly, Maria Barcikowska, Zbigniew K Wszolek, Dennis W Dickson, Neill R Graff-Radford, Ronald C Petersen, Peter Passmore, Kevin Morgan, Steven G Younkin
Institutions: Mayo Clinic, Mayo Clinic in Florida, University of Nottingham, Hospital de Sant Pau, Queen's Medical Centre, Norwegian University of Science and Technology, St Olav's University Hospital, Mossakowski Medical Research Institute, Polish Academy of Sciences, Polish Academy of Sciences, Queen's University Belfast
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,090
Funders: University of Southampton, University of Oxford, University of Leeds, Queen's University Belfast, University of Bristol, Queen's University, Rheinische Friedrich-Wilhelms-Universität Bonn, National Institutes of Health, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: G1133087115, Plasma AB as a Surrogate Genetic Marker for LOAD, Einstein Aging Study, Biomarkers for Preclinical Parkinson's disease, G5426926231, PD iPS Cell Line Research Consortium, Florida Alzheimer's Disease Research, Tau and Neurodegeneration II: A therapeutic target, Genetics and Molecular Biology of Parkinsonism, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2169103586
